Urothelial Carcinoma
Conditions
Brief summary
This is a single arm phase II study assessing the activity of atezolizumab in combination with carboplatin + gemcitabine or docetaxel compared to historical controls of chemotherapy only in metastatic or recurrent urothelial carcinoma subjects. Subjects that received a PD 1 or PD-L1 inhibitor with no prior platinum chemotherapy for metastatic disease will be treated with atezolizumab + carboplatin + gemcitabine on trial. Subjects that received sequential or concurrent PD1/PDL1 inhibitor and carboplatin-based regimen will be treated with atezolizumab + docetaxel on trial.
Interventions
DRUGCarboplatin
Carboplatin AUC 4 IV Day 1 of each 21 day cycle
DRUGGemcitabine
Gemcitabine 1,000 mg/m2 IV Day 1 and Day 8 of each 21 day cycle
DRUGAtezolizumab
Atezolizumab 1,200 mg IV Day 1 of each 21 day cycle
DRUGDocetaxel
Docetaxel 75 mg/m2 IV Day 1 of each 21 day Cycle.
Sponsors
Genentech, Inc.
Indiana University School of Medicine
Nabil Adra
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. * Age ≥ 18 years at the time of consent. * ECOG Performance Status of 0-2 within 28 days prior to registration. * Histological or cytological confirmed metastatic or unresectable locally advanced urothelial carcinoma (primary tumor: renal pelvis, ureters, urinary bladder, or urethra). * Patients with mixed histologies are eligible. * Cisplatin ineligible at the time of diagnosis with metastatic urothelial carcinoma based on consensus definition with any of the following criteria: ECOG PS 2, creatinine clearance \< 60mL/min, CTCAE v4 grade ≥ 2 hearing loss, CTCAE v4 grade ≥ 2 peripheral neuropathy, New York Heart Association (NYHA) class ≥ 3 heart failure. * Measurable disease according to RECIST 1.1 within 28 days prior to registration. * Must have had progressive metastatic disease after previous treatment with PD-1 or PD-L1 inhibitor (in the adjuvant or metastatic setting). Treatment regimen will be determined based on prior treatment: * PD1 or PDL1 inhibitor with no prior platinum chemotherapy for metastatic disease. These patients should be treated with atezolizumab + carboplatin + gemcitabine on trial. * Sequential or concurrent PD1/PDL1 inhibitor and carboplatin-based regimen. These patients should be treated with atezolizumab + docetaxel on trial. * Most recent therapy does not have to have been a checkpoint inhibitor. Intercurrent treatment is acceptable if subjects meet all other inclusion criteria. * A subject with prior brain metastasis may be considered if they have completed their treatment for brain metastasis at least 4 weeks prior to study registration, have been off of corticosteroids for ≥ 2 weeks, and are asymptomatic. * Previous neoadjuvant or adjuvant chemotherapy that was completed 6 months prior to study enrollment is allowed. * REQUIRED archival tumor tissue (prior to treatment with single agent PD-1 or PD-L1 inhibitor) must be identified prior to registration and obtained during the screening period. Confirmation of acquisition should occur prior to C1D1 treatment. Unavailability of tissue will render the subject ineligible for study. Biopsy should be excisional, incisional or core needle. Fine needle aspiration is insufficient. Sample requirement is FFPE block + 1 H&E stained slide or 25 unstained slides + 1 H&E stained slide. * Demonstrate adequate organ function as defined in the table below. All screening labs to be obtained within 28 days prior to registration. * White blood cell (WBC) ≥ 2 k/mm3 * Absolute Neutrophil Count (ANC) ≥ 1.5 K/mm3 * Hemoglobin (Hgb) ≥ 9 g/dL * Platelet \>100k * Estimated creatinine clearance ≥ 30 mL/min * Bilirubin 1.5 ≤ (ULN) * Aspartate aminotransferase (AST) ≤ 1.5 × ULN * Alanine aminotransferase (ALT) ≤ 1.5 × ULN * International Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT) ≤ 2 × ULN (Note: This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose) * Females of childbearing potential (FOCBP) must have a negative serum pregnancy test within 28 days prior to registration. These women must also have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of atezolizumab then every 6 weeks thereafter. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is post-menopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 62 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL. * Females of childbearing potential and males must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 150 days (5 months) after treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method. * Men who are sexually active with FOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving atezolizumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 150 days (5 months) after the last dose of investigational product. * As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.
Exclusion criteria
* Previous autoimmune complication from PD-1 or PD-L1 inhibitor requiring permanent discontinuation of therapy. * Previous permanent discontinuation from PD-1 or PD-L1 inhibitor due to an adverse event (patients who had temporary holds or discontinuation of PD-1 or PD-L1 inhibitor and then re-treated are eligible). * Any serious or uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy. * Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study). * 5\. Has a known additional malignancy that is progressing or required treatment ≤ 48 months of study registration. Exceptions: include malignancies with negligible risk of metastasis or death treated with expected curative outcome or undergoing surveillance per investigator's discretion (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, ductal carcinoma in situ treated surgically with curative intent, or very low risk or low risk prostate cancer per NCCN guidelines). * Active central nervous system (CNS) metastases. Subjects with brain metastases are eligible if metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression within 28 days prior to the first dose of atezolizumab administration. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (\> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration. * Treatment with any investigational drug within 30 days prior to registration. * Subjects with an active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids/immunosuppressive medications EXCEPT for syndromes which would not be expected to recur in the absence of an external trigger. (Subjects with vitiligo, autoimmune thyroiditis, or type I diabetes mellitus are permitted to enroll.). * As there is potential for hepatic toxicity with atezolizumab, drugs with a predisposition to hepatoxicity should be used with caution in subjects treated with atezolizumab-containing regimen. * Subjects should be excluded if they have known history of testing positive for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection. Testing is not required. * Subjects should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). Testing is not required. * History of allergy to atezolizumab or respective chemotherapy regimen (carboplatin + gemcitabine or docetaxel).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | From C1D1 until progression or death or up to a maximum of 26 months | Evaluate PFS among patients to be treated with atezolizumab in combination with carboplatin + gemcitabine or docetaxel, who have cisplatin-ineligible metastatic urothelial carcinoma and who have progressed on prior PD-1 or PD-L1 inhibitor. PFS defined as duration from date of treatment start until progression according to RECIST 1.1 criteria, or death from any cause. Per RECIST 1.1 criteria, Progressive disease can be defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) With RECIST 1.1 | From C1D1 until death or up to a maximum of 28 months. | Objective response rate (ORR) using RECIST 1.1 defined as the proportion of all subjects with confirmed PR or CR according to RECIST 1.1, from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the start of treatment). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR |
| Objective Response Rate (ORR) With irRECIST | From C1D1 until death or up to a maximum of 28 months. | ORR defined as the proportion of all subjects with confirmed PR or CR using immunerelated response criteria (irRECIST), from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the start of treatment). Per irRECIST for target lesions Complete Response (irCR), Disappearance of all target lesions; Partial Response (irPR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = irCR + irPR. |
| Clinical Benefit Rate (CBR) With RECIST 1.1 | From C1D1 until death or up to a maximum of 28 months. | Clinical benefit rate (CBR) of treatment (defined by proportion of all subjects with stable disease for at least 3 months, partial response, or complete response) using RECIST 1.1 from the start of treatment until disease/recurrence(taking as reference for progressive disease the smallest measurements recorded since the start of treatment). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter since the treatment started; Clinical Benefit Rate (CBR) = CR +PR +SD (for atleast 3 months). |
| Clinical Benefit Rate (CBR) With irRECIST | From C1D1 until death or up to a maximum of 28 months. | Clinical benefit rate (CBR) of treatment (defined by proportion of all subjects with stable disease for at least 3 months, partial response, or complete response) using irRECIST from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the start of treatment). Per irRECIST for target lesions: Complete Response (irCR), Disappearance of all target lesions; Partial Response (irPR), \>=30% decrease in the sum of the longest diameter of target lesions, neither sufficient shrinkage to qualify for irPR nor sufficient increase to qualify for irPD, taking as reference the smallest sum longest diameter since the treatment started; Clinical Benefit Rate (CBR) = irCR +irPR +irSD (for atleast 3 months). |
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Carboplatin + Gemcitabine or Docetaxel | From C1D1 until death or up to a maximum of 8 months | Assess the safety and tolerability of the combination of atezolizumab plus chemotherapy (carboplatin + gemcitabine or docetaxel) using CTCAE v4.03. Number of subjects who had any adverse events or events greater than grade 3 were reported in this outcome measure. |
| Overall Survival (OS) | From C1D1 until death or up to a maximum of 28 months | OS defined by the date of treatment start to date of death from any cause. |
| Progression Free Survival (PFS) Compared to Historical Controls | From C1D1 until progression or death or up to a maximum of 26 months | To compare Progression Free Survival(PFS) with the historical control, Null hypothesis - Patients receiving atezolizumab plus chemotherapy (carboplatin +gemcitabine or docetaxel) will have a median PFS of 4 months. Alternative hypothesis - Patients receiving atezolizumab plus chemotherapy (carboplatin + gemcitabine or docetaxel) will have a median PFS of 7.2 months. Progression Free Survival defined as duration from date of treatment start until progression according to RECIST 1.1 criteria, or death from any cause.Per RECIST 1.1 criteria, Progressive disease can be defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions. |
| Progression Free Survival (PFS) for Atezolizumab + Carboplatin and Gemcitabine | From C1D1 until death or progression or up to a maximum of 26 months | Evaluate PFS for atezolizumab + carboplatin and gemcitabine. PFS defined as duration from date of treatment start until progression according to RECIST 1.1 criteria, or death from any cause.Per RECIST 1.1 criteria, Progressive disease can be defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions. |
| Progression Free Survival (PFS) for Atezolizumab + Docetaxel | From C1D1 until progression or death | Evaluate PFS for atezolizumab + docetaxel. PFS defined as duration from date of treatment start until progression according to RECIST 1.1 criteria, or death from any cause. Per RECIST 1.1 criteria, Progressive disease can be defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions. |
| PFS by irRECIST | From C1D1 until progression or death or up to a maximum of 26 months | PFS defined as duration from date of treatment start until progression according to irRECIST criteria or death from any cause. Per irRECIST criteria, Progressive disease can be defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Phase IIA : Atezolizumab + Carboplatin + Gemcitabine Subjects that received a PD 1 or PD-L1 inhibitor with no prior platinum chemotherapy for metastatic disease will be treated with atezolizumab + carboplatin + gemcitabine on trial.
Carboplatin: Carboplatin AUC 4 IV Day 1 of each 21 day cycle
Gemcitabine: Gemcitabine 1,000 mg/m2 IV Day 1 and Day 8 of each 21 day cycle
Atezolizumab: Atezolizumab 1,200 mg IV Day 1 of each 21 day cycle | 6 |
| Phase IIB : Docetaxel + Atezolizumab Subjects that received sequential or concurrent PD1/PDL1 inhibitor and carboplatin-based regimen will be treated with docetaxel + atezolizumab on trial.
Docetaxel: Docetaxel 75 mg/m2 IV Day 1 of each 21 day Cycle.
Atezolizumab: Atezolizumab 1,200 mg IV Day 1 of each 21 day cycle. | 0 |
| Total | 6 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Follow up | Death | 1 | 0 |
| Follow up | Termination of study | 4 | 0 |
| Follow up | Withdrawal by Subject | 1 | 0 |
| Study Treatment | Adverse Event | 2 | 0 |
| Study Treatment | Disease Progression | 2 | 0 |
| Study Treatment | Withdrawal by Subject | 2 | 0 |
Baseline characteristics
| Characteristic | Total | Phase IIA : Atezolizumab + Carboplatin + Gemcitabine | Phase IIB : Docetaxel + Atezolizumab |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 6 Participants | 6 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants |
| ECOG Performance Status 0 | 4 Participants | 4 Participants | 0 Participants |
| ECOG Performance Status 1 | 2 Participants | 2 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 1 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 5 Participants | 5 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 5 Participants | 5 Participants | 0 Participants |
| Sex: Female, Male Female | 1 Participants | 1 Participants | 0 Participants |
| Sex: Female, Male Male | 5 Participants | 5 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 1 / 6 |
| other Total, other adverse events | 6 / 6 |
| serious Total, serious adverse events | 3 / 6 |
Outcome results
Primary
Progression Free Survival (PFS)
Evaluate PFS among patients to be treated with atezolizumab in combination with carboplatin + gemcitabine or docetaxel, who have cisplatin-ineligible metastatic urothelial carcinoma and who have progressed on prior PD-1 or PD-L1 inhibitor. PFS defined as duration from date of treatment start until progression according to RECIST 1.1 criteria, or death from any cause. Per RECIST 1.1 criteria, Progressive disease can be defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.
Time frame: From C1D1 until progression or death or up to a maximum of 26 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase IIA : Atezolizumab + Carboplatin + Gemcitabine | Progression Free Survival (PFS) | 11.3 months |
Secondary
Clinical Benefit Rate (CBR) With irRECIST
Clinical benefit rate (CBR) of treatment (defined by proportion of all subjects with stable disease for at least 3 months, partial response, or complete response) using irRECIST from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the start of treatment). Per irRECIST for target lesions: Complete Response (irCR), Disappearance of all target lesions; Partial Response (irPR), \>=30% decrease in the sum of the longest diameter of target lesions, neither sufficient shrinkage to qualify for irPR nor sufficient increase to qualify for irPD, taking as reference the smallest sum longest diameter since the treatment started; Clinical Benefit Rate (CBR) = irCR +irPR +irSD (for atleast 3 months).
Time frame: From C1D1 until death or up to a maximum of 28 months.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase IIA : Atezolizumab + Carboplatin + Gemcitabine | Clinical Benefit Rate (CBR) With irRECIST | 100 percentage of participants |
Secondary
Clinical Benefit Rate (CBR) With RECIST 1.1
Clinical benefit rate (CBR) of treatment (defined by proportion of all subjects with stable disease for at least 3 months, partial response, or complete response) using RECIST 1.1 from the start of treatment until disease/recurrence(taking as reference for progressive disease the smallest measurements recorded since the start of treatment). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter since the treatment started; Clinical Benefit Rate (CBR) = CR +PR +SD (for atleast 3 months).
Time frame: From C1D1 until death or up to a maximum of 28 months.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase IIA : Atezolizumab + Carboplatin + Gemcitabine | Clinical Benefit Rate (CBR) With RECIST 1.1 | 100 percentage of participants |
Secondary
Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Carboplatin + Gemcitabine or Docetaxel
Assess the safety and tolerability of the combination of atezolizumab plus chemotherapy (carboplatin + gemcitabine or docetaxel) using CTCAE v4.03. Number of subjects who had any adverse events or events greater than grade 3 were reported in this outcome measure.
Time frame: From C1D1 until death or up to a maximum of 8 months
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase IIA : Atezolizumab + Carboplatin + Gemcitabine | Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Carboplatin + Gemcitabine or Docetaxel | Number of patients had at least one grade 3 or greater adverse event | 6 Participants |
| Phase IIA : Atezolizumab + Carboplatin + Gemcitabine | Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Carboplatin + Gemcitabine or Docetaxel | Number of patients had at least one adverse event of any grade | 6 Participants |
| Phase IIA : Atezolizumab + Carboplatin + Gemcitabine | Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Carboplatin + Gemcitabine or Docetaxel | Number of patients had at least one grade 3 or greater treatment related adverse event | 6 Participants |
| Phase IIA : Atezolizumab + Carboplatin + Gemcitabine | Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Carboplatin + Gemcitabine or Docetaxel | Number of patients having serious adverse event | 3 Participants |
Secondary
Objective Response Rate (ORR) With irRECIST
ORR defined as the proportion of all subjects with confirmed PR or CR using immunerelated response criteria (irRECIST), from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the start of treatment). Per irRECIST for target lesions Complete Response (irCR), Disappearance of all target lesions; Partial Response (irPR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = irCR + irPR.
Time frame: From C1D1 until death or up to a maximum of 28 months.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase IIA : Atezolizumab + Carboplatin + Gemcitabine | Objective Response Rate (ORR) With irRECIST | 40 percentage of participants |
Secondary
Objective Response Rate (ORR) With RECIST 1.1
Objective response rate (ORR) using RECIST 1.1 defined as the proportion of all subjects with confirmed PR or CR according to RECIST 1.1, from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the start of treatment). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Time frame: From C1D1 until death or up to a maximum of 28 months.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase IIA : Atezolizumab + Carboplatin + Gemcitabine | Objective Response Rate (ORR) With RECIST 1.1 | 40 percentage of participants |
Secondary
Overall Survival (OS)
OS defined by the date of treatment start to date of death from any cause.
Time frame: From C1D1 until death or up to a maximum of 28 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase IIA : Atezolizumab + Carboplatin + Gemcitabine | Overall Survival (OS) | NA months |
Secondary
PFS by irRECIST
PFS defined as duration from date of treatment start until progression according to irRECIST criteria or death from any cause. Per irRECIST criteria, Progressive disease can be defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.
Time frame: From C1D1 until progression or death or up to a maximum of 26 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase IIA : Atezolizumab + Carboplatin + Gemcitabine | PFS by irRECIST | 11.3 months |
Secondary
Progression Free Survival (PFS) Compared to Historical Controls
To compare Progression Free Survival(PFS) with the historical control, Null hypothesis - Patients receiving atezolizumab plus chemotherapy (carboplatin +gemcitabine or docetaxel) will have a median PFS of 4 months. Alternative hypothesis - Patients receiving atezolizumab plus chemotherapy (carboplatin + gemcitabine or docetaxel) will have a median PFS of 7.2 months. Progression Free Survival defined as duration from date of treatment start until progression according to RECIST 1.1 criteria, or death from any cause.Per RECIST 1.1 criteria, Progressive disease can be defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.
Time frame: From C1D1 until progression or death or up to a maximum of 26 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase IIA : Atezolizumab + Carboplatin + Gemcitabine | Progression Free Survival (PFS) Compared to Historical Controls | 11.3 months |
Secondary
Progression Free Survival (PFS) for Atezolizumab + Carboplatin and Gemcitabine
Evaluate PFS for atezolizumab + carboplatin and gemcitabine. PFS defined as duration from date of treatment start until progression according to RECIST 1.1 criteria, or death from any cause.Per RECIST 1.1 criteria, Progressive disease can be defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.
Time frame: From C1D1 until death or progression or up to a maximum of 26 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase IIA : Atezolizumab + Carboplatin + Gemcitabine | Progression Free Survival (PFS) for Atezolizumab + Carboplatin and Gemcitabine | 11.3 months |
Secondary
Progression Free Survival (PFS) for Atezolizumab + Docetaxel
Evaluate PFS for atezolizumab + docetaxel. PFS defined as duration from date of treatment start until progression according to RECIST 1.1 criteria, or death from any cause. Per RECIST 1.1 criteria, Progressive disease can be defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.
Time frame: From C1D1 until progression or death
Population: No subject was enrolled in this arm.